How do you monitor and manage minimal residual disease (MRD) in patients with core-binding factor (CBF) AML who are in remission post-induction and consolidation therapy?

For the purposes of this question, we will presume this refers to patients who are MRD-negative by a PCR-based methodology and have completed induction chemotherapy and consolidation.

Puckrin et al., PMID 31896684 reported on 114 patients with CBF-AML who were treated with intensive chemotherapy and had MRD monitoring every 3 months. Molecular relapse was defined as ≥1 log increase in transcript level between two samples, while morphologic relapse was defined as ≥5% blasts. Of the 43 patients who...